1. Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.
- Author
-
Top S, Foulon E, Pignolet B, Deplanche M, Caubet C, Tasca C, Bertagnoli S, Meyer G, and Foucras G
- Subjects
- Animals, Cells, Cultured, Drug Evaluation methods, Gene Expression Profiling, Myxoma virus genetics, Rabbits, Sheep, Vaccines, Attenuated genetics, Vaccines, Attenuated immunology, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Viral Vaccines genetics, Dendritic Cells immunology, Dendritic Cells virology, Drug Carriers, Gene Expression, Genetic Vectors, Myxoma virus immunology, Viral Vaccines immunology
- Abstract
Recombinant myxoma virus (MYXV) can be produced without a loss of infectivity, and its highly specific host range makes it an ideal vaccine vector candidate, although careful examination of its interaction with the immune system is necessary. Similar to rabbit bone marrow-derived dendritic cells (BM-DCs), ovine dendritic cells can be infected by SG33, a MYXV vaccine strain, and support recombinant antigen expression. The frequency of infected cells in the nonhost was lower and the virus cycle was abortive in these cell types. Among BM-DC subpopulations, Langerhans cell-like DCs were preferentially infected at low multiplicities of infection. Interestingly, ovine BM-DCs remained susceptible to MYXV after maturation, although apoptosis occurred shortly after infection as a function of the virus titer. When gene expression was assessed in infected BM-DC cultures, type I interferon (IFN)-related and inflammatory genes were strongly upregulated. DC gene expression profiles were compared with the profiles produced by other poxviruses in interaction with DCs, but very few commonalities were found, although genes that were previously shown to predict vaccine efficacy were present. Collectively, these data support the idea that MYXV permits efficient priming of adaptive immune responses and should be considered a promising vaccine vector along with other poxviruses.
- Published
- 2011
- Full Text
- View/download PDF